首页> 外文期刊>Radiation Oncology Journal >Postoperative radiotherapy for mucoepidermoid carcinoma of the major salivary glands: long-term results of a single-institution experience
【24h】

Postoperative radiotherapy for mucoepidermoid carcinoma of the major salivary glands: long-term results of a single-institution experience

机译:主要唾液腺粘液表皮样癌的术后放疗:单机构经验的长期结果

获取原文
       

摘要

Purpose This study aimed to evaluate the long-term survival outcomes and prognostic factors that affect the clinical outcomes of patients who underwent surgery and postoperative radiotherapy for major salivary gland mucoepidermoid carcinoma (MEC). Materials and Methods We retrospectively reviewed the clinical data of 44 patients who underwent surgery followed by radiotherapy for primary MEC of the major salivary glands between 1991 and 2014. The median follow-up period was 9.8 years (range, 0.8 to 23.8 years). Results The overall outcomes at 5 and 10 years were 81.5% and 78.0% for overall survival (OS), 86.2% and 83.4% for disease-free survival, 90.6% and 87.6% for locoregional recurrence-free survival, and both 90.5% for distant metastasis-free survival (DMFS). Histologic grade was the only independent predictor of OS (low vs. intermediate vs. high; hazard ratio = 3.699; p = 0.041) in multivariate analysis. A poorer survival was observed among patients with high-grade tumors compared with those with non-high-grade tumors (5-year OS, 37.5% vs. 91.7%, p 0.001; 5-year DMFS, 46.9% vs. 100%, p 0.001). Conclusion Surgery and postoperative radiotherapy resulted in excellent survival outcomes for patients with major salivary gland MEC. However, high-grade tumors contributed to poor DMFS and OS. Additional aggressive strategies for improving survival outcomes should be developed for high-grade MEC.
机译:目的本研究旨在评估影响主要唾液腺粘液表皮样癌(MEC)的手术和术后放疗的患者的长期生存结局和影响其临床结局的预后因素。资料与方法我们回顾性分析了1991年至2014年间主要唾液腺原发性MEC接受手术后放疗的44例患者的临床资料。中位随访时间为9.8年(范围为0.8至23.8年)。结果5年和10年的总生存率分别为:总生存率(OS)为81.5%和78.0%,无病生存率分别为86.2%和83.4%,局部无复发生存率分别为90.6%和87.6%和90.5%。无远处转移生存期(DMFS)。在多因素分析中,组织学分级是OS的唯一独立预测因子(低vs.中vs.高;危险比= 3.699; p = 0.041)。与非高级别肿瘤患者相比,高级别肿瘤患者的生存期较差(5年OS,37.5%比91.7%,p <0.001; 5年DMFS,46.9%比100% ,p <0.001)。结论手术和术后放疗可为重度涎腺MEC患者带来出色的生存结果。然而,高度肿瘤导致不良的DMFS和OS。对于高级MEC,应制定其他改善生存结果的积极策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号